IDiyas

For the Inventor, By the Inventor

Ventura, CA, United States of America

Matthew R Kaller

USPTO Granted Patents = 37 

 

 

Average Co-Inventor Count = 12.6

ph-index = 10

Forward Citations = 149(Granted Patents)


Location History:

  • Ventura, CA (US) (2004 - 2021)
  • Thousand Oaks, CA (US) (2020 - 2022)

Company Filing History:

goldMedal37 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2004-2025

where 'Filed Patents' based on already Granted Patents

37 patents (USPTO):
1. 12441736 - KIF18A inhibitors (2025-10-14),
2. 12435058 - KIF18A inhibitors (2025-10-07),
3. 11224601 - Compounds that inhibits MCL-1 protein (2022-01-18),
4. 11046680 - Heteroaryl-substituted triazoles as APJ receptor agonists (2021-06-29),
5. 10821115 - Compounds that inhibit Mcl-1 protein (2020-11-03),
6. 10632128 - Compounds that inhibit Mcl-1 protein (2020-04-28),
7. 10221162 - Triazole agonists of the APJ receptor (2019-03-05),
8. 10058550 - Methods of treating heart failure (2018-08-28),
9. 9868721 - Triazole agonists of the APJ receptor (2018-01-16),
10. 9845310 - Intermediates for preparing triazole agonists of the APJ receptor (2017-12-19),
11. 9751864 - Methods for preparing triazole agonists of the APJ receptor (2017-09-05),
12. 9745286 - Triazole agonists of the APJ receptor (2017-08-29),
13. 9656998 - Intermediates for preparing triazole agonists of the APJ receptor (2017-05-23),
14. 9656997 - Triazole agonists of the APJ receptor (2017-05-23),
15. 9573936 - Triazole agonists of the APJ receptor (2017-02-21),

Title: Unveiling the Innovations of Inventor Matthew R Kaller

Introduction:

Matthew R Kaller is a distinguished inventor based in Ventura, CA (US) who has made significant contributions to the field of pharmaceuticals and biotechnology. With an impressive portfolio of 35 patents, his research has focused on developing compounds for the treatment of various diseases, including cancer and cardiovascular conditions.

Latest Patents:

Two of his latest patents showcase his expertise in drug discovery and development:

1. Compounds that inhibit MCL-1 protein: These inhibitors target the Mcl-1 protein, offering promising possibilities for cancer treatment.

2. Heteroaryl-substituted triazoles as APJ receptor agonists: These compounds act as agonists of the APJ Receptor, potentially aiding in treatments for cardiovascular and related conditions.

Career Highlights:

Matthew R Kaller is a key figure at Amgen Inc., a leading biotechnology company known for its groundbreaking research and development in the healthcare industry. His role at Amgen Inc. has enabled him to transform innovative ideas into tangible solutions that impact global health.

Collaborations:

In his journey of innovation, Matthew R Kaller has collaborated with esteemed professionals in the field, including Daniel B Horne and Thomas T Nguyen. These collaborations have fostered a dynamic environment for brainstorming ideas and translating them into patented inventions that push the boundaries of scientific advancement.

Conclusion:

Inventor Matthew R Kaller's relentless pursuit of scientific excellence has solidified his position as a visionary in the realm of pharmaceutical inventions. His valuable contributions not only enhance the existing body of knowledge but also pave the way for future breakthroughs in medicine and healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…